Sep 28, 2023 14:49 JST

Source: Eisai

Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"

Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed “Dementia Care Support Insurance” to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.

Background

Tokio Marine Nichido and Eisai concluded a business alliance agreement for the realization of a Dementia Inclusive Society in August 2019, and the two companies have promoted initiatives to achieve this purpose, including the provision since April 2021 of “NouKNOW” (1), a digital tool for self-assessment of cognitive function developed by Eisai, as an ancillary service for “Long-term care indemnity (installment payment)”, sold by Tokio Marine Nichido.

Dementia was thought to be difficult to treat, but with the approval of a new drug for Alzheimer's disease, which accounts for 60% of dementia cases, and the hope of slowing disease progression by starting treatment in the early stages of disease, the preparation for early detection and early treatment is becoming increasingly important.

Amid such circumstances, the two companies co-developed a new insurance product, “Dementia Care Support Insurance” to financially support early detection and early treatment of the disease, with the expertise Tokio Marine Nichido has developed through dealing with insurance products and related services and Eisai’s extensive experience in the field of dementia.

Overview of (Industry’s First(2)) “Dementia Care Support Insurance”

a.  Details of Coverage/Service

The new treatment is indicated for patients with mild cognitive impairment and mild cognitive impairment due to Alzheimer's disease, but determination of eligibility requires medical tests, including a PET scan, to confirm amyloid-β pathology. Since these tests and treatments require a certain level of out-of-pocket expenses, the following coverage will be provided for financial support.

- Lump-sum benefit for mild cognitive impairment (Support for early detection)

In the event of the first diagnosis of mild cognitive impairment (including dementia), a lump sum benefit for the purpose of covering costs for amyloid PET tests, etc. is provided.

- Lump-sum benefit for mild cognitive impairment due to Alzheimer’s disease (Support for early stage treatment)

In the event of the first diagnosis of mild cognitive impairment due to Alzheimer’s disease (including dementia due to Alzheimer’s), a lump-sum benefit for the purpose of covering medical costs for treatment with the new drug is provided.

Additionally, the policy provides the opportunity to use “NouKNOW” as an ancillary service, ensuring the support of early detection and early treatment by identifying cognitive decline.

b. Process Upon Signing The Policy

Potential policy holders need to complete a “NouKNOW" test to purchase the policy, along with completing a Statement of Health form.

c. Insurance Premium

Monthly 1,370 yen (in the case of a male aged 50 to 54 years receiving a 300,000 yen lump-sum benefit for mild cognitive impairment, and 1 million yen for mild cognitive impairment due to Alzheimer's disease). *May vary depending on terms of contract

d. Type of Policy

A group insurance in which a large-scale entity, such as a company, purchases the policy and its members voluntarily purchase the coverage through the entity.

3. Future Perspectives

Tokio Marine Nichido and Eisai will further promote efforts to resolve various social challenges by expanding our network through collaboration with various companies and organizations, to realize a Dementia Inclusive Society.

(1) A tool for checking brain reaction speed, attention, visual learning and memory through four types of simple tests with images of playing cards on a PC, tablet, or smartphone. (Not a medical device)
(2) The first coverage in the non-life insurance industry focusing on mild cognitive impairment due to Alzheimer’s disease and dementia due to Alzheimer’s disease (according to a survey conducted by Tokio Marine Nichido)
(3) May vary depending on terms of contract

Media Contacts:

Tokio Marine & Nichido Fire Insurance Co., Ltd.
Public Relations:
TEL:+81-(0)3-6704-4268

Eisai Co., Ltd.
Public Relations:
TEL:+81-(0)3-3817-5120 

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
More Press release >>

Latest Press Release


More Latest Release >>